Atypical Antipsychotics in the Treatment of Affective Symptoms: A Review

References

• Peuskens J, Van Baelen B, De Smedt C, Lemmens P: Effects of risperidone on affective symptoms in patients with schizophrenia. In Clin Psychopharmacol 2000; 15:343–349.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM: Anxious-depressive symptoms in schizophrenia: A new treatment target for pharmaco-therapy? Schizophr Res 1999; 35(Suppl 3):S13—S21.
   Google Scholar
• Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S: Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47–60.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB: An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000; 61:19–25.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP: The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000; April (Special Report):1–104.
   Google Scholar
• Zarate CA, Vemuri M, Cavanagh S, Land M: Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders. Curr Psychiatry Rep 2000; 2:291–297.
   Google Scholar
• American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002; 159 (4 Suppl):1–50.
   Web of Science ®Google Scholar
• Ghaemi SN, Goodwin FK: Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999; 19:354–361.
   PubMedGoogle Scholar
• Ghaemi SN: New treatments for bipolar disorder: The role of atypical neuroleptic agents. J Clin Psychiatry 2000; 61(Suppl 14):33–42.
   PubMed Web of Science ®Google Scholar
• Kaplan M: Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000; 61: 388–389.
   PubMed Web of Science ®Google Scholar
• Keck PE, Strakowski SM, McElroy SL: The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(Suppl 3):4–9.
   PubMedGoogle Scholar
• Schweitzer I: Does risperidone have a place in the treatment of nonschizophrenic patients? Int Clin Psychopharmacol 2001; 16:1–19.
   PubMed Web of Science ®Google Scholar
• Worrel JA, Marken PA, Beckman SE, Ruehter VL: Atypical antipsychotic agents: A critical review. Am J Health Syst Pharm 2000; 57:238–255.
   PubMed Web of Science ®Google Scholar
• Bowden CL: Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10:661–671.
   PubMed Web of Science ®Google Scholar
• Glick RU, Ghaemi SN: The emergency treatment of depression complicated by psychosis or agitation. J Clin Psychiatry 2000; 61(Suppl 14):43–48.
   Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13:25–40.
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765–774.
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835.
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997; 58:538–546.
   PubMed Web of Science ®Google Scholar
• Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712–726.
   PubMed Web of Science ®Google Scholar
• Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS: Different side effect profiles of risperidone and clozapine in 20 out-patients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996; 153:417–419.
   PubMedGoogle Scholar
• Masand PS: Weight gain associated with psychotropic drugs. Exp Opin Pharmacother 2000; 1:377–389.
   PubMedGoogle Scholar
• Masand PS, Gupta S: Long-term adverse effects of novel antipsychotics. J Psychiatric Practice 2000; 6: 299–309.
   PubMedGoogle Scholar
• Myers JE, Mahmoud R, Berry SA, Conley RR: Risperi-done versus olanzapine for the treatment of mood symp-toms in patients with schizophrenia or schizoaffective disorder. Presented at: Fourth International Meeting of the College of Psychiatric and Neurologic Pharmacists; March 25–28,2001; San Antonio, Texas.
   Google Scholar
• Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21:176–180.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159:1146–1154.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–147.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V: Risperidone in acute and continuation treatment of mania. RIS-CAN 25 Study Group. Int Clin Psychopharmacol 2003; 18:227–235.
   PubMed Web of Science ®Google Scholar
• Zyprexae (olanzapine) Prescribing Information. Eli Lilly and Company. Indianapolis, IN, USA. Literature revised February 16,2001.
   Google Scholar
• Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V: Olanzapine versus placebo in the treatment of acute mania. The Olanzapine HGEH Study Group. Am J Psychiany 1999; 156:702–709.
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A: Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841–849.
   PubMed Web of Science ®Google Scholar
• Chengappa KNR, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ: Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003; 5:1–5.
   PubMed Web of Science ®Google Scholar
• Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD: Acute dysphoric mania: Treatment response to olanza-pine versus placebo. J Clin Psychopharmacol. 2003; 23:132–137.
   PubMed Web of Science ®Google Scholar
• Berk M, Ichim L, Brook S: Olanzapine compared to lithium in mania: A double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999; 14:339–343.
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011–1017.
   PubMed Web of Science ®Google Scholar
• Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P. Sommerville KW: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63:1148–1155.
   Google Scholar
• Koller E, Malozowski S, Doraiswamy PM: Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286:2547–2548.
   Google Scholar
• Mir S, Taylor D: Atypical antipsychotics and hypergly-caemia. Int Clin Psychopharmacol. 2001; 16:63–73.
   PubMed Web of Science ®Google Scholar
• Muench J, Carey M: Diabetes mellitus associated with atypical antipsychotic medications: New case report and review of the literature. J Am Board Fam Pract. 2001; 14:278–282.
   Google Scholar
• Selva KA, Scott SM: Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001; 138:936–938.
   PubMed Web of Science ®Google Scholar
• Von Hayek D, Huttl V, Reiss J, Schweiger HD, Fuessl HS: [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt 1999; 70:836–837.
   Google Scholar
• Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425–433.
   PubMed Web of Science ®Google Scholar
• Gianfi-ancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 2002; 63:920–930.
   Google Scholar
• Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216–1223.
   PubMed Web of Science ®Google Scholar
• Chisholm K, Suppes T: Clinical response to quetiapine add-on for treatment refractory bipolar disorder. Abstract presented at the Fourth International Conference on Bipolar Disorder; June 14–16,2001; Pittsburgh, Pa.
   Google Scholar
• Ghaemi SN, Goldberg IF, Ko JY, Oakley L: Seroquel treatment of rapid-cycling bipolar disorder: an open prospective study. Abstract presented at the Fourth International Conference on Bipolar Disorder; June 14–16,2001; Pittsburgh, Pa.
   Google Scholar
• Vieta E, Parramon G, Padrell E, Nieto E, Martinez-Arán A, Corbella B, Colom F, Reinares M, Goikolea JM, Torrent C: Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4:335–340.
   PubMed Web of Science ®Google Scholar
• Keck PE, Reeves KR, Harrigan EP: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies. Ziprasidone Study Group. J Clin Psychopharmacol 2001; 21:27–35.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Ziprasidone in Mania Study Group. Am J Psychiatry 2003; 160:741–748.
   Google Scholar
• Guille C, Sachs GS, Ghaemi SN: A naturalistic com-parison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61:638–642.
   PubMed Web of Science ®Google Scholar
• Miiller-Siecheneder F, Milner MJ, Hillert A, Szegedi A, Wetzel H, Benkert 0: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998; 18:111–120.
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Ander-sen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17:407–418.
   PubMed Web of Science ®Google Scholar
• Myers JE, Mahmoud R, Keith SJ, Berry S, Csernansky JG: Long-term benefit of risperidone versus haloperi-dol for affective symptoms in patients with schizophre-nia and schizoaffective disorder. Presented at: Thirty-ninth Annual Meeting of the American College of Neuro-psychopharmacology; December 10–14, 2000; San Juan, Puerto Rico.
   Google Scholar
• Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: A double-blind, randomized compari-son of olanzapine and risperidone. Biol Psychiatry 1999; 46:365–373.
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depres-sion. J Clin Psychiatry 1999; 60:256–259.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Addington S, Augenstein E, Ball W: Risperi-done and paroxetine in bipolar depression. Presented at the Annual Meeting of the American Psychiatric Association; May 5–10,2001; New Orleans, LA.
   Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457–465.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250–258.
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60:116–118.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131–134.
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacer-bation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233–246.
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG: Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54:549–557.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J: Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 61:185–189.
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20:491–505.
   PubMed Web of Science ®Google Scholar